Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.

Respiratory research - 16 Dec 2023

Martin Christian, Guzior Douglas V, Gonzalez Cely T, Okros Maxwell, Mielke Jenna, Padillo Lienwil, Querido Gabriel, Gil Marissa, Thomas Ryan, McClelland Marc, Conrad Doug, Widder Stefanie, Quinn Robert A

Abstract excerpt

BACKGROUND: Cystic fibrosis (CF) is a genetic disorder causing poor mucociliary clearance in the airways and subsequent respiratory infection. The recently approved triple therapy Elexacaftor-Tezacaftor-Ivacaftor (ETI) has significantly improved lung function and decreased airway infection in persons with CF (pwCF). This improvement has been shown to occur rapidly, within the first few weeks of treatment. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Dynamics Simulation

Share to Mutation

Share to RNA, Ribosomal, 16S

Source

Open in PubMed Open full text

Identifiers

PMID: 38104128
DOI: 10.1186/s12931-023-02630-z
PMCID: PMC10725582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.PMID 38104128Read ↗

Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapySemantic proximity Read ↗

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosisSemantic proximity Read ↗

Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche spaceSemantic proximity Read ↗

High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic TherapySemantic proximity Read ↗

Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapySemantic proximity Read ↗

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.Semantic proximity Read ↗

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read ↗

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-IvacaftorSemantic proximity Read ↗

Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the NewSemantic proximity Read ↗

Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic FibrosisSemantic proximity Read ↗

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: an open-label proof-of-concept studySemantic proximity Read ↗

Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky SituationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.